Vimarsana
Biggest News Aggregation in the World

Page 12 - Jonathan Silverberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Silverberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Silverberg Today - Breaking & Trending Today

LEO Pharma announces FDA approval of Adbry™ (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis - Vimarsana News

LEO Pharma announces FDA approval of Adbry™ (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis

LEO Pharma A/S, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab) ...

IL-13 Inhibitor Approved for Adults With Atopic Dermatitis - Vimarsana News

IL-13 Inhibitor Approved for Adults With Atopic Dermatitis

Significantly greater lesion clearance with tralokinumab in placebo-controlled studies

Association of Height, BMI, and AD in Young Children May Be Transient - Vimarsana News

Association of Height, BMI, and AD in Young Children May Be Transient

'The potential for 'catch up' in height for children with atopic dermatitis observed in our study may be explained with resolution of atopic dermatitis or successful treatment,' the authors write.

UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis - Vimarsana News

UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis

/PRNewswire/ -- UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases,...

Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials - Vimarsana News

Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com